Mechanisms of tissue injury in autoimmune liver diseases.
about
NK Cell Subtypes as Regulators of Autoimmune Liver DiseaseXenobiotics and loss of tolerance in primary biliary cholangitisThe Role of Genetic and Immune Factors for the Pathogenesis of Primary Sclerosing Cholangitis in ChildhoodWhy Doesn't Primary Biliary Cholangitis Respond to Immunosuppressive Medications?Innate immunity drives the initiation of a murine model of primary biliary cirrhosis.The role of natural killer T cells in a mouse model with spontaneous bile duct inflammation.CYP2E1 autoantibodies in liver diseasesIL-35 and Autoimmunity: a Comprehensive Perspective.Novel therapeutic targets in primary biliary cirrhosis.The coexistence of Sjögren's syndrome and primary biliary cirrhosis: a comprehensive review.Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis.Human autoimmune diseases: a comprehensive update.Obeticholic acid for the treatment of primary biliary cirrhosis.The functional characteristics CCNI modulation of myeloid- derived suppressor cells in liver inflammation.Crosstalk between type II NKT cells and T cells leads to spontaneous chronic inflammatory liver disease.Management of cholestatic disease in 2017.Decreased serum DNase1-activity in patients with autoimmune liver diseases.Animal models of primary biliary cirrhosis.The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.The cumulative effects of known susceptibility variants to predict primary biliary cirrhosis risk.Immunological potential of cytotoxic T lymphocyte antigen 4 immunoglobulin in murine autoimmune cholangitis.Novel strategies and therapeutic options for the management of primary biliary cholangitis.Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort.Unmet challenges in immune-mediated hepatobiliary diseases.Investigational drugs in phase II clinical trials for primary biliary cholangitis.
P2860
Q26741392-D818E370-8552-4122-9DA0-20495C7AFE41Q26772312-D4255EF4-9837-4799-81EE-2EC0846BD187Q28068996-7AEF37FC-6B42-404D-BED2-0EC5DA46A94DQ33840969-7418D709-7AB6-4514-A516-E9A1402DC7E0Q35217545-D4A3F5D2-5BBE-4DC1-B5A6-0EB59147CB2CQ37670243-F7A0F24E-7033-4A6A-A708-B617D072C099Q38280871-610F19A9-54D0-412E-AAFA-7137A45B97A0Q38331780-3B8DA5C3-13BF-463D-B603-ECD5327E5F9BQ38342107-FC0A5F91-BB32-4163-ACE9-01F946096C94Q38355697-18DAA511-4215-47A0-A2BB-D26B6117651AQ38374504-90AD9EBF-9900-45F1-929D-586BF8394AC1Q38554722-3001B004-9210-4F27-AF46-5A796F057AA0Q38628470-FE42834F-EA68-4540-BCB7-96CE49C7476AQ38640611-83D034F2-C68E-4EC2-9952-E3DA179B19FDQ38735507-D36D2135-58F4-438C-B465-6DC3056D6A2AQ38774857-E4EFC9C5-C749-4CB9-A423-9A8FC6546E84Q40306774-FAE8F80E-E3FE-4DD3-BF63-225D0EB92C56Q41221983-594045AD-1E25-40D1-A4A3-609A6A4A8066Q41303819-F1AB6513-54B5-473B-9707-DADD1DCF7A85Q41365044-23A038C7-C6DC-4093-BC15-98827EC52E7DQ41592947-923AC28E-CD40-4A3E-BAAD-42B16CA8EAAFQ42375647-DEDD5C21-F492-4ADE-888C-18BC12BCBE5BQ47135110-BD7270B3-8BE0-4D97-8E26-3860D584AA0BQ48542369-2A34822A-F6F7-4BC0-A4B3-599BE2B06B6DQ53098304-E838CBB3-A0C0-47EF-AA4D-9B84175B94A5
P2860
Mechanisms of tissue injury in autoimmune liver diseases.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Mechanisms of tissue injury in autoimmune liver diseases.
@en
type
label
Mechanisms of tissue injury in autoimmune liver diseases.
@en
prefLabel
Mechanisms of tissue injury in autoimmune liver diseases.
@en
P2860
P1476
Mechanisms of tissue injury in autoimmune liver diseases.
@en
P2093
Evaggelia Liaskou
P2860
P2888
P304
P356
10.1007/S00281-014-0439-3
P577
2014-08-01T00:00:00Z
P5875
P6179
1010149372